-
Mashup Score: 363
Abstract. B12 deficiency is the leading cause of megaloblastic anemia, and although more common in the elderly, can occur at any age. Clinical disease caused by
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 554Iron deficiency: new insights into diagnosis and treatment - 3 day(s) ago
Abstract. Iron deficiency and iron deficiency anemia are common conditions worldwide affecting especially children and young women. In developing countries, iro
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Iron Deficiency Differential Diagnosis Table! Many have tried to make this table, however, I assure you this is the most complete and best version [courtesy of ASH Education Book]! https://t.co/E1aBzlaEo8…… https://t.co/YPF5nzKO2N
-
-
Mashup Score: 67
Disclosures. Guru Murthy:Syndax: Other: Advisory Board; Autolus: Other: Advisory board; Pfizer: Other: Advisory board; BMS: Other: Advisory Board; Amgen: C
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
This data cannot be used to make medical decisions for patients with AML. If you died waiting to start therapy you were not included in this analysis. Bottom line, if you think patient needs treatment for AML please start. Don’t wait for NGS. https://t.co/n5qLeb2yCp
-
-
Mashup Score: 22Meet ABIM’s new leader: alleviating physician burnout - 11 day(s) ago
A conversation with Furman S. McDonald, MD, MPH.
Source: www.medicaleconomics.comCategories: General Medicine News, Hem/OncsTweet-
ABIM new CEO cares about physician burnout! You can't make this sh*t up. https://t.co/dchZPCqOzZ via @@medeconomics
-
-
Mashup Score: 113Hormonal therapies and venous thrombosis: Considerations for prevention and management - 16 day(s) ago
Venous thromboses are well‐established complications of hormonal therapy. Thrombosis risk is seen with both hormonal contraceptive agents and with hormone replacement therapy for menopause and gender transition. Over the past several decades, large epidemiological studies have helped better define these risks.
Source: www.rpthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Awesome paper on hormonal therapies, thrombosis, and what to do about it! @Bloodman to the rescue Hormonal therapies and venous thrombosis: Considerations for prevention and management - Research and Practice in Thrombosis and Haemostasis https://t.co/45tLLmsi0Q
-
-
Mashup Score: 38Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma - 20 day(s) ago
Key Points. SOC cilta-cel in RRMM results in deep and durable response despite over half the patients not meeting CARTITUDE-1 eligibility criteria.Close su
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Cilta cel in real world 10% non relapse mortality with only 13 month follow up. Sounds like an excellent drug for smoldering myeloma and frontline Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma https://t.co/x1m8kiywwv
-
-
Mashup Score: 224t(6;9)(p22;q34) DEK/NUP214 - 1 month(s) ago
Please, confirm that you want to generate a PDF file of this page. This may take some seconds once process has started. Then it will be opened automatically.
Source: atlasgeneticsoncology.orgCategories: General Medicine News, Hem/OncsTweet-
AML Heme Path Pearl! AML with t(6;9) [DEK-NUP214] 1% of AMLs Associated with basophilia! Frequent FLT3 ITD mutations Poor prognosis (5 year OS = 30%) Rx = intensive induction +/- FLT3 inhibitor or ven/aza Consolidate = allogeneic transplant if able. https://t.co/LDmZ7I09oZ https://t.co/WUK4n4dgLb
-
-
Mashup Score: 10Sign the Petition - 1 month(s) ago
Eliminate ABIMs MOC requirement
Source: www.change.orgCategories: General Medicine News, Hem/OncsTweet-
@VPrasadMDMPH Sign the petition https://t.co/JKZF57DFlH
-
-
Mashup Score: 1222025 update on clinical trials in immune thrombocytopenia - 2 month(s) ago
Summary of major novel and repurposed agents currently in clinical development for immune thrombocytopenia.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Time to get my classical heme on for a tough case of refractory ITP. This seems like a solid up to date review (also free) @Bloodman American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/aaOOox1uN5
-
-
Mashup Score: 75
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: – Cilta-cel (or chimeric antigen receptor T cells) – Cyclophosphamide (a lymphodepleting chemotherapy) – Fludarabine (a lymphodepleting chemotherapy)
Source: www.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet-
The US medical system in all its glory! You can you be completely healthy, get a lab test checked you never needed, and end up receiving a toxic million dollar therapy with risks of secondary cancers and long term neurologic side effects. CAR-PRISM https://t.co/OGkPp1s431
-
This is quite the diagram for B12 absorption and metabolism. Time to commit to memory so I can impress people on rounds. Thank you Dr. Ralph Green and @BloodJournal for making dreams come true. https://t.co/N8GTxx4QF6 https://t.co/J8vmV23U2e